Updates are available Correction dated 2019-03-06
Click to view Correction: https://doi.org/10.1186/s40425-019-0547-7
-
Authors
Smith, Kellie N.
Llosa, Nicolas J.
Cottrell, Tricia R.
Siegel, Nicholas
Fan, Hongni
Suri, Prerna
Chan, Hok Yee
Guo, Haidan
Oke, Teniola
Awan, Anas H.
Verde, Franco
Danilova, Ludmila
Anagnostou, Valsamo
Tam, Ada J.
Luber, Brandon S.
Bartlett, Bjarne R.
Aulakh, Laveet K.
Sidhom, John-William
Zhu, Qingfeng
Sears, Cynthia L.
Cope, Leslie
Sharfman, William H.
Thompson, Elizabeth D.
Riemer, Joanne
Marrone, Kristen A.
Naidoo, Jarushka
Velculescu, Victor E.
Forde, Patrick M.
Vogelstein, Bert
Kinzler, Kenneth W.
Papadopoulos, Nickolas
Durham, Jennifer N.
Wang, Hao
Le, Dung T.
Justesen, Sune
Taube, Janis M.
Diaz, Luis A.
Brahmer, Julie R.
Pardoll, Drew M.
Anders, Robert A.
Housseau, Franck https://orcid.org/0000-0002-7028-3953
-
Funding
Funding for this research was provided by:
National Cancer Institute (R01 CA203891, R01 CA121113)
Cancer Research Institute (#)
Stand Up To Cancer (SU2C-AACR-DT1012)
Commonwealth Foundation (#)
-
More Information
Article History
Received: 14 September 2018
Accepted: 20 December 2018
First Online: 11 February 2019
Change Date: 6 March 2019
Change Type: Correction
Change Details: .
Ethics approval and consent to participate
: The patients described in this study provided written informed consent as approved by the IRB of Johns Hopkins.
: Not applicable.
: K.N.S., F.H., D.M.P, V.A., B.V., K.W.K., N.P., L.A.D, and V.E.V. have filed for patent protection on a subset of the technologies described herein (US provisional application no. 62/407,820). D.M.P. has ownership interest (including patents) in BMS, MedImmune/AstraZeneca, and Potenza, and is a consultant/advisory board member for BMS and MedImmune/AstraZeneca. V.E.V. has ownership interest (including patents) in Personal Genome Diagnostics and is a consultant/advisory board member for the same.
: Springer Nature remains neutral with regard to jurisdictional claims in published maps and institutional affiliations.
